Which STDs Are Not Curable? Common Lifelong Infections

Four sexually transmitted infections remain incurable with current medicine: herpes simplex virus (HSV-1 and HSV-2), human immunodeficiency virus (HIV), hepatitis B virus (HBV), and, in a more conditional sense, human papillomavirus (HPV). Each persists for different biological reasons, from viral DNA hiding inside nerve cells to proviral genomes tucked into immune cells. Effective treatments exist for all four, and for some the gap between “managed” and “cured” has narrowed dramatically, but none can be fully eliminated from the body once established.

Herpes Simplex Virus

HSV is the most common incurable STI worldwide. It comes in two types: HSV-1, historically associated with oral cold sores but increasingly responsible for genital infections, and HSV-2, which primarily causes genital herpes. Both types establish lifelong infection through the same trick: after the initial outbreak, the virus retreats into nerve cells in sensory ganglia and goes dormant. In this latent state, the virus is essentially invisible to the immune system. It does not replicate in the usual sense. Instead, it maintains its genetic material inside neurons while expressing only a narrow set of viral genes, which alters how infected nerve cells function without triggering an immune alarm.

The virus can reactivate periodically, traveling back down nerve fibers to the skin or mucous membranes to produce new viral particles. Reactivation can be triggered by a range of stimuli, from stress and illness to UV exposure, each activating different cellular processes that restart viral gene expression.

What makes HSV particularly stubborn is that antiviral drugs like valacyclovir and famciclovir work only against actively replicating virus. They cannot touch the latent copies sitting quietly in neurons. Daily suppressive therapy with valacyclovir significantly reduces viral shedding: in one trial, shedding dropped from about 11 percent of days on placebo to roughly 3 percent on the drug, a reduction of around 78 percent.

In a separate large trial, valacyclovir cut the rate of HSV-2 DNA detection in genital secretions from about 11 percent of days to 3 percent, and also halved the risk of transmitting the infection to an uninfected partner.

HIV and Its Hidden Reservoir

HIV has gone from a death sentence to a manageable chronic condition thanks to antiretroviral therapy (ART). People on effective ART can live normal lifespans and, when their viral load is undetectable, cannot sexually transmit the virus, a principle widely known as “Undetectable equals Untransmittable” or U=U.

Yet HIV remains incurable because of a biological obstacle that has frustrated researchers for decades: the latent reservoir. Soon after infection, HIV inserts its genetic material into the DNA of certain immune cells, particularly long-lived memory CD4 T cells. Some of these cells enter a resting state where the virus sits silently integrated into the host genome, producing no viral proteins and drawing no attention from the immune system or from antiretroviral drugs.

ART suppresses active viral replication effectively, but it cannot purge these dormant copies. The reservoir is remarkably stable, with an estimated half-life so long that existing drugs alone would take many decades to clear it. If a person stops ART, the virus rebounds from this reservoir within weeks, typically restarting active infection. This persistence has been confirmed repeatedly: the latent reservoir in resting memory CD4 T cells is the principal barrier to an HIV cure.

Researchers are exploring several strategies to overcome this. One approach, sometimes called “shock and kill,” aims to force latent virus out of hiding so the immune system or a therapeutic agent can destroy the newly activated cells. Laboratory studies using CRISPR-based gene-editing tools have shown they can reactivate dormant HIV genomes from within cells, producing levels of viral activation comparable to or higher than established drug-based methods.

A combined strategy pairing CRISPR activation with a cell-suicide gene showed a roughly 58 percent reduction in the HIV-positive cell population in lab experiments, illustrating how forcing the virus out of latency while simultaneously killing the host cell could chip away at the reservoir.

Other gene-editing approaches aim to cut the viral DNA directly out of infected cells’ genomes. CRISPR-Cas systems have been recognized as promising tools for this kind of targeted gene therapy against HIV, though all of these strategies remain in early research stages and face enormous challenges in safely reaching every reservoir cell in a living person.

Chronic Hepatitis B

Hepatitis B deserves a more nuanced discussion than the others because its outcome depends heavily on when a person is infected. Adults who contract HBV clear it on their own about 95 percent of the time. But infants infected at birth develop chronic infection in roughly 90 percent of cases, and for those with chronic HBV, the infection is effectively lifelong.

The reason chronic HBV persists is a molecular structure called covalently closed circular DNA, or cccDNA. When HBV infects a liver cell, it converts its genome into this stable, ring-shaped form that takes up residence in the cell’s nucleus. This cccDNA serves as the sole template for making new viral genomes, and it is stubbornly durable. Current antiviral drugs, primarily nucleoside and nucleotide analogues, can suppress active viral replication very effectively, but they do not eliminate the cccDNA sitting inside liver cells.

This means that if treatment is stopped, the virus can reactivate from those remaining cccDNA templates. The goal of therapy for chronic hepatitis B is therefore to suppress viral replication enough to prevent the liver damage that leads to cirrhosis and liver cancer. Two main treatment strategies exist: a finite course of pegylated interferon (usually about a year) or longer-term therapy with antiviral drugs. Long-term viral suppression does reduce the risk of disease progression substantially. In one study, maintaining an undetectable viral load for more than 12 months reduced the risk of liver cancer development dramatically compared to those with shorter periods of suppression.

Vaccination remains the most powerful tool against hepatitis B. The HBV vaccine is highly effective at preventing infection in the first place, and universal infant vaccination programs have drastically reduced new chronic cases in countries where they have been implemented. For those already chronically infected, though, a true cure that eliminates cccDNA from liver cells remains elusive.

HPV and the Question of Clearance

HPV sits in an unusual middle ground. Most HPV infections are cleared by the immune system within one to two years without any treatment, and the person is no longer infectious afterward. In that sense, calling HPV universally “incurable” overstates the case. But a minority of infections persist, particularly those involving high-risk strains like HPV-16 and HPV-18. These persistent infections are the ones that can progress to cervical, throat, anal, and other cancers over many years.

There is no antiviral drug that targets HPV itself. The body’s immune response is the only mechanism that clears the virus, and researchers have found that the vaginal microbiome may play a role in whether clearance happens. Women whose cervicovaginal microbiome was dominated by a particular species of beneficial bacteria showed faster HPV clearance and higher rates of regression of precancerous cervical changes, while a different microbial profile was associated with slower clearance.

HPV vaccines are extremely effective at preventing infection with the most dangerous strains but do not treat existing infections. For persistent HPV that causes precancerous lesions, treatment involves removing the abnormal tissue (through procedures like excision or ablation), not eliminating the virus itself. Some of these patients do eventually clear the virus after treatment, but others do not, and ongoing screening is necessary.

Why Hepatitis C Is the Exception

People often lump all viral hepatitis together, so it is worth noting why hepatitis C (HCV) is now considered curable while hepatitis B is not. The difference comes down to how the two viruses store their genetic material. HCV replicates using RNA and does not integrate into the host cell’s DNA or form a stable reservoir equivalent to HBV’s cccDNA. This made it possible to develop direct-acting antivirals, drugs that block specific proteins HCV needs to replicate. These medications can achieve cure rates above 95 percent in just 8 to 12 weeks of treatment.

No equivalent breakthrough exists for the other incurable STIs because their persistence mechanisms are fundamentally different. HSV hides as latent DNA in neurons that live for decades. HIV integrates into the host genome of long-lived immune cells. HBV maintains a stable DNA template in the nucleus of liver cells. Each of these storage strategies makes the virus far harder to reach and eliminate than a virus replicating freely via RNA in the bloodstream.

How Incurable STIs Interact With Each Other

Having one incurable STI can increase your vulnerability to others, a relationship that is especially well-documented between HSV-2 and HIV. Active HSV-2 infection, even without visible sores, draws high concentrations of activated CD4 T cells to the genital area. These are exactly the cells HIV needs to infect. HSV-2 can also cause breaks in the mucosal barrier through which HIV can enter. Because genital shedding is most frequent early in HSV-2 infection, the increase in HIV susceptibility may be greatest in the first year after acquiring herpes.

The relationship works in the other direction too. Co-infection with HIV increases HSV-2 shedding and transmissibility, while HSV-2 infection correlates with higher HIV viral levels and greater HIV transmissibility. This bidirectional amplification is one reason public health strategies treat HSV-2 control as part of HIV prevention, and why getting tested for one infection often prompts screening for others.

Testing and the Window Period Problem

One challenge with incurable STIs is that testing is not as straightforward as many people assume. Each infection has a window period, the time between exposure and when a test can reliably detect the infection. During this window, you can be infected and potentially infectious but test negative.

For HSV-2, blood-based antibody tests have high sensitivity (estimated at about 92 percent) but the window period can extend up to 12 weeks after exposure. Someone who tests negative immediately after a potential exposure should be retested at 12 weeks to get a reliable result.

HIV testing windows have shortened considerably with modern fourth-generation tests that detect both antibodies and viral antigen, but a window of several weeks still applies depending on the test type. HBV surface antigen can take one to nine weeks to appear, and HPV has no routine blood test at all. For HPV, detection relies on swab-based DNA tests or Pap smears, which detect the virus’s effects on cells rather than antibodies in the blood.

These window periods matter because a false-negative result during the window can lead someone to believe they are uninfected and unknowingly transmit the virus. If you have had a specific exposure event, the timing of your test relative to that exposure determines how much you can trust a negative result.

The Psychological Weight of a Lifelong Diagnosis

Receiving a diagnosis of an incurable STI carries a psychological burden that goes beyond physical symptoms, and for many people the emotional impact is actually worse than the medical one. Genital herpes is a useful case study here because its physical symptoms are often mild or absent, yet the diagnosis can be devastating.

Research on women living with genital herpes found that perceived stigma, coping strategies, and sources of social support together accounted for about 66 percent of the variation in quality of life scores. Acceptance-based coping helped, while denial coping was associated with worse outcomes. The interaction between stigma and coping was complex: high perceived stigma could undermine even constructive coping strategies.

A broader review of the psychological literature on genital herpes stigma described a self-reinforcing cycle. Negative feelings about the diagnosis and poor coping can trigger more frequent outbreaks, since stress is a known reactivation trigger. More frequent outbreaks make the stigma feel more salient, reinforcing a stigmatized sense of self, which in turn perpetuates the distress.

This cycle is not inevitable. People who find effective support, whether through informed healthcare providers, online communities, or personal networks, tend to adjust well over time. But the initial period after diagnosis is often the hardest, and the cultural weight attached to the word “incurable” can be disproportionate to the actual medical impact of many of these infections.

What “Incurable” Actually Means Day to Day

For most people living with an incurable STI, the practical reality is far less dramatic than the label suggests. Someone with genital herpes who takes daily suppressive medication may go years without an outbreak and poses minimal transmission risk to partners. A person with HIV on effective ART has an undetectable viral load, cannot transmit the virus sexually, and faces life expectancy close to that of the general population.¹ Someone with chronic hepatitis B on antiviral therapy can keep their viral load suppressed and dramatically reduce their risk of liver disease.² And the majority of HPV infections resolve entirely on their own without the person ever knowing they were infected.

The word “incurable” accurately describes the biology, but it can mislead people into imagining constant illness or inevitable decline. In most cases, the experience of living with one of these infections is defined far more by medication adherence, regular monitoring, and emotional adjustment than by the virus itself. The gap between what people fear when they hear “no cure” and what daily life actually looks like with modern treatment is, for most of these infections, enormous.

Pregnancy and Vertical Transmission

For people with incurable STIs who want to have children, preventing transmission to the baby during pregnancy and delivery is a major concern, and the strategies vary by infection. Maternal HIV is managed with ART throughout pregnancy, which reduces the risk of mother-to-child transmission to below 1 percent when viral load is well suppressed.³ For hepatitis B, newborns receive both the HBV vaccine and hepatitis B immune globulin within hours of birth, a protocol that is highly effective at preventing chronic infection even when the mother has a high viral load.

Herpes poses its greatest risk during delivery if the mother is having an active outbreak, particularly a primary (first-ever) outbreak near the time of birth. In that scenario, cesarean delivery is typically recommended to avoid exposing the newborn to the virus in the birth canal. Women with a history of genital herpes but no active lesions at the time of delivery generally deliver vaginally, often with suppressive antiviral therapy started in the final weeks of pregnancy to reduce the chance of an outbreak.

HPV can occasionally be transmitted during delivery, but this is uncommon and rarely causes serious disease in the newborn. The much larger concern with HPV is its long-term cancer risk in the infected person, not vertical transmission.

Where Cure Research Stands

Research aimed at true cures is most advanced for HIV, where the stakes are highest and funding has been most substantial. The handful of people who have been functionally cured of HIV received bone marrow transplants from donors with a rare genetic mutation that makes cells resistant to HIV entry. This approach is far too risky and complex for widespread use but has provided proof of concept that a cure is biologically possible.

Gene-editing tools, particularly CRISPR-Cas systems, are being explored as a way to either cut HIV’s integrated DNA out of host cells or to modify a patient’s own immune cells to resist infection.⁴ Lab studies using CRISPR-derived activator systems have demonstrated reactivation of dormant HIV proviral DNA at levels comparable to or exceeding established drug-based latency reversing agents.⁵ When combined with a suicide gene approach, this technique reduced the HIV-positive cell population by roughly 58 percent in lab models.⁶

For hepatitis B, the central challenge is destroying cccDNA in liver cells. Several companies are developing drugs that target cccDNA directly or aim to boost the immune response against infected hepatocytes, but none has yet reached late-stage clinical trials with results demonstrating functional cure.⁷ For herpes, the challenge of targeting virus hidden in neurons is particularly steep, and therapeutic vaccines aimed at reducing recurrences (rather than curing the infection) have had disappointing results in trials so far. HSV cure research is further behind HIV and HBV, partly because herpes is rarely life-threatening and attracts less funding as a result.